Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Net Cash Flow (2016 - 2025)

Guided Therapeutics' Net Cash Flow history spans 15 years, with the latest figure at -$96000.0 for Q3 2025.

  • For Q3 2025, Net Cash Flow fell 18.52% year-over-year to -$96000.0; the TTM value through Sep 2025 reached -$105000.0, up 80.45%, while the annual FY2024 figure was -$203000.0, 88.21% up from the prior year.
  • Net Cash Flow for Q3 2025 was -$96000.0 at Guided Therapeutics, down from $70000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $2.2 million in Q3 2022 and bottomed at -$627000.0 in Q3 2023.
  • The 5-year median for Net Cash Flow is -$146000.0 (2024), against an average of -$4157.9.
  • The largest annual shift saw Net Cash Flow surged 690.03% in 2022 before it plummeted 680.49% in 2023.
  • A 5-year view of Net Cash Flow shows it stood at $102000.0 in 2021, then crashed by 476.47% to -$384000.0 in 2022, then soared by 63.54% to -$140000.0 in 2023, then soared by 238.57% to $194000.0 in 2024, then plummeted by 149.48% to -$96000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Net Cash Flow are -$96000.0 (Q3 2025), $70000.0 (Q2 2025), and -$273000.0 (Q1 2025).